Analyst Upgrades: Lululemon Athletica inc., GlaxoSmithKline plc., and Xerox Corporation

Analysts upwardly revised their ratings on Lululemon Athletica inc. (LULU), GlaxoSmithKline plc (ADR) (GSK), and Xerox Corp (XRX)

by Griffin Kruse

Published on Apr 8, 2015 at 9:09 AM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on yoga apparel maker Lululemon Athletica inc. (NASDAQ:LULU), pharmaceutical firm GlaxoSmithKline plc (ADR) (NYSE:GSK), and business technology company Xerox Corp (NYSE:XRX). Here's a quick roundup of today's bullish brokerage notes on LULU, GSK, and XRX.

  • Sterne Agee raised its opinion on LULU to "buy" from "neutral," sending the shares about 2.5% higher in electronic trading. The upgrade is unsurprising, given the shares of Lululemon Athletica inc. have added over 19% year-to-date to close yesterday at $66.41. Options traders have been bearish on the stock, though, as LULU's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.32 stands in the 96th percentile of its annual range. Likewise, more than 10% of LULU's float is dedicated to short interest, representing more than seven sessions' worth of pent-up buying demand, at the stock's average pace of trading.

  • The shares of GSK are up 1.5% ahead of the bell, after Deutsche Bank raised its price target on the equity to 1,600P from 1,300P while keeping its "hold" rating. On the charts, GlaxoSmithKline plc has been on the mend in 2015, with the shares up 14.6% from their Jan. 6 three-year low of $41.25 to close Tuesday at $47.26. Despite this positive price action, puts have grown increasingly popular in the options pits. Specifically, over the past 10 days at the ISE/CBOE/PHLX, 0.43 GSK puts have been bought to open for every call, which is a higher ratio than 72% of all similar readings from the past year. Mirroring this indicator is the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.05, which stands in the 94th percentile of its annual range. Simply stated, near-term speculators have rarely been this put-heavy over the past year.

  • Citigroup weighed in on XRX, upgrading its rating to "buy" from "neutral" and lifting its price target to $15 from $12.50. Looking back, Xerox Corp has been a technical outperformer, with the shares advancing roughly 12.8% year-over-year to finish yesterday's session at $12.96. What's more, the shares are 2.6% higher in pre-market trading today. Although XRX's technical performance over the past year has been impressive, options traders have stayed skeptical of the security. Drilling down, XRX's 50-day ISE/CBOE/PHLX put/call volume ratio of 0.47 stands in the 82nd percentile of all similar annual readings, and an unwinding of this pessimism could provide tailwinds for the shares.

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Google Postpones Android Reveal, "Now is Not the Time to Celebrate"
"Now is not the time to celebrate," Google said in a message on its website
ZNGA Zooms to 8-Year High on Billion-Dollar Deal
ZNGA is planning to buy Peak for $1.8 billion
Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....